The solution integrates medical and drug claims data from the IBM MarketScan research databases into Aetion’s Evidence Platform. Biopharma companies can now use the platform to analyze claims data to find answers to questions about the safety, medical affairs and market access of the treatments they develop.
Available analyses include feasibility counts, prevalence and incidence, disease burden, population exploration, drug treatment pathways, hypothesis generation, comparative safety and comparative effectiveness.
“Historically, substantial investment in real-world evidence has been almost the exclusive domain of large pharma,” Carolyn Magill, Aetion CEO, said in a news release. “By combining IBM Watson Health’s data source and a best-in-class analytics platform in this bundled offering, innovative midmarket biopharma companies can now benefit from integrating real-world data into drug development and commercialization to help them solve data-driven challenges.”
More articles on health IT:
University Hospitals receives $15M for men’s healthcare innovation
Washington University School of Medicine notifies patients of data breach
Google developing enhanced search functions for EHRs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
